The Multiple Ion Channel Blocker CPUY11018 Prevents Aconitine‐Induced Arrhythmias
Yi-Qun Tang,Peng Yu,Na Zhao,Qian Yang,Yue-Miao Yin,Xiao-Yong Le,Xiang Guo,Min-Hui Wang,Hao Zhong,Qi-Dong You
DOI: https://doi.org/10.1002/ddr.21009
2012-01-01
Drug Development Research
Abstract:Strategy, Management and Health Policy Enabling Technology, Genomics, Proteomics Preclinical Research Preclinical Development Toxicology, Formulation Drug Delivery, Pharmacokinetics Clinical Development Phases I-III Regulatory, Quality, Manufacturing Postmarketing Phase IV In the present study, the potential antiarrhythmic activities of a new multiple ion channel blocker, CPUY11018 (Y18) were investigated. The effects of Y18 on ICa,L and INa were studied using whole-cell patch clamp techniques in ventricular muscle cells from normal rats and guinea pigs. The antiarrhythmic effects were tested using a rat model of aconitine-induced arrhythmias. The effects of Y18 on induction of QT prolongation and torsades de pointes (TdP) were investigated in anesthetized rabbits during stimulation with methoxamine. Y18 produced a concentration-dependent inhibition of ICa,L and INa in rat ventricular myocytes with IC50 values of 88?mu mol/l and 6.5 mu mol/l, respectively. In the Y18 treatment group, the development of arrhythmias was significantly delayed. Doses of aconitine that induced ventricular fibrillation were decreased following treatment with 6?mg/kg Y18 (3.8 +/- 0.4 mu g/100?g vs 6.2 +/- 1.3 mu g/kg). A significant decrease in the occurrence of atrial fibrillation (100% to 33%; P?<?0.05) occurred following Y18 administration. Y18 induction of TdP was significantly less than that seen with dofetilide and azimilide (Az). Thus, Y18 significantly inhibited the production of aconitine-induced arrhythmias with a low potency for TdP induction. These results suggest that Y18 is a multiple channel blocker with promising antiarrhythmic potential.